
CDCã®ãç匟ãç ç©¶ïŒ ãã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ãæ¥çš®ããåäŸã¯æªæ¥çš®è ãããCOVIDææçã«ãããå¯èœæ§ãé«ãã
å èšäºã¯ãã¡ããã/Click here to read the original article.
å ç«åŠè ã§å¿èèžéšå€ç§å»ã®ããŒãã³ã»ããŒãã£ã·ã¥ã å»åŠå士ã¯ããã®ç ç©¶ã¯èªç¶å ç«ããã¯ã¯ãã³å ç«ããã广çãã§ãããCOVID-19ã®æ³šå°ã¯åäŸã«ã¯äžèŠã§ããããšããæ±ºå®çã«èšŒæããŠããããšè¿°ã¹ãã
ç±³ãã¡ã€ã¶ãŒç€Ÿã®COVID-19ã¯ã¯ãã³ãæ¥çš®ãã5æ³æªæºã®åäŸãã¡ã¯ãèªç¶å ç«ã®ããæªæ¥çš®ã®åäŸãã¡ãããCOVID-19ã«ææããå¯èœæ§ãé«ãããšããç±³çŸç 察çäºé²ã»ã³ã¿ãŒïŒCDCïŒã®ç§åŠè ãã¡ã«ãã ãç匟ç ããªæ»èªä»ãç ç©¶ã®ããŒã¿ãã倿ããã
ãããã仿åãã«ãJournal of Pediatric Infectious Diseases SocietyïŒå°å ææçåŠäŒèªïŒãã«çºè¡šããããã®ç ç©¶ã®èè ãã¡ã¯ãçµè«ã®äžã§ãã®çºèŠã匷調ããªãã£ãããã®ä»£ããã«ããæžããŠããïŒ
ãSARS-CoV-2ææã®æ¢åŸã®ããåå è ã¯ãæ¢åŸã®ãªãåå è ã«æ¯ã¹ãŠãSARS-CoV-2ã«ææããçåæ§COVID-19ãçµéšããå¯èœæ§ãäœãã£ãã
ãçåŸ6ã¶æãã4æ³ã®å°å ã«ãããSARS-CoV-2ææãšçåæ§COVID-19ã®ãªã¹ã¯ã«ã¯ã¯ã¯ãã³æ¥çš®ã®æç¡ã«ããå·®ã¯ãªãã£ãããSARS-CoV-2ææã®æ¢åŸã¯äž¡æ¹ã®çºççã®äœäžãšé¢é£ããŠãããã
èè ãã¯ãCOVID-19ã®ã¯ã¯ãã³æ¥çš®ã ãéçåãæãããã ãã«æšå¥šãããããå šäœçãªææãªã¹ã¯ã¯ãã¯ã¯ãã³æ¥çš®ãåãã5æ³æªæºå ãšåããŠããªã5æ³æªæºå ã®éã§å€§ããªå·®ã¯ãªããããããªã ããšèªããŠããã
ããŒããŒã倧åŠå»åŠéšã®å ææã§ãã°ã¬ãŒãã»ããªã³ãã³å®£èšã®å ±èè ã§ããããŒãã£ã³ã»ã¯ã«ãã«ãå士ã¯ããDefenderãçŽã«å¯Ÿããããã®ç ç©¶ã¯ãCOVIDææåŸãå°ãªããšã1幎éã¯åŒ·ãèªç¶å ç«ãæç¶ããããšãäºæ³éã瀺ããŠããããšèªã£ãã
å ç«åŠè ã§å¿èèžéšå€ç§å»ã®ããŒãã³ã»ããŒãã£ã·ã¥ã å»åŠå士ïŒç±³åœæ£è æè·åçã®åµèšè ïŒã¯ããã®ç ç©¶ã¯èªç¶å ç«ããã¯ã¯ãã³å ç«ããã广çãã§ããããšããæ±ºå®çã«èšŒæããŠããããšããCOVID-19ã®äºé²æ³šå°ã¯å°å ã«ã¯äžèŠã§ãããšè¿°ã¹ãã
ãå°å éå£ã«ãããSARS-CoV-2ææã®çœ¹æ£çãæ»äº¡çã®ãªã¹ã¯ã®äœããã¯ã¯ãã³ã«é¢é£ããæå®³äºè±¡ã®çŸå®ãèæ ®ãããšãå°å éå£ã«COVID-19ã¯ã¯ãã³æ¥çš®ã矩åä»ããããããã¯æšå¥šããåççãªæ ¹æ ã¯ãªãã
ã¯ã¯ãã³æ¥çš®ãåããåäŸã¯191ïŒ ã®ç¢ºçã§çåæ§COVIDãšèšºæããã
ããã«ããŒè²¡å£ã®ç«åŠè ã§ãããã³ã©ã¹ã»ãã¥ã«ã·ã£ãŒã¯ããã®ç ç©¶ã¯ã¯ã¯ãã³ããæ³å®ããŠããããšãšå察ã®ããšããããããšã瀺ããŠãããšè¿°ã¹ããCOVID-19ãã身ãå®ãã©ãããããããã®éºäŒå泚å°ã¯å€±æããããææã®ãªã¹ã¯ãå¢å€§ãããã®ã§ããã
ãšããã®ãããã®ç ç©¶ã®éèŠãªçºèŠã®ã²ãšã€ã¯ãæ·»ä»ã®è¡šã§æããã«ãããŠããããèè ãã¯åŒ·èª¿ããŠããªãããã¡ã€ã¶ãŒç€Ÿã®COVID-19ã¯ã¯ãã³ãæ¥çš®ããåäŸãã¡ã¯ãã¯ã¯ãã³æªæ¥çš®ã®åäŸãã¡ãããçåæ§COVID-19ææãèµ·ããå¯èœæ§ãé«ãããã¶ãŒãæ¯ïŒHRïŒã¯2.91ã95ïŒ ä¿¡é ŒåºéïŒCIïŒã¯1.12-7.53ã§ãã£ãã
ãã¶ãŒãæ¯ãšã¯ãããäºè±¡ãåãæéã«ãã矀ã§ä»ã®çŸ€ã«æ¯ã¹ãŠã©ã®çšåºŠé »ç¹ã«èµ·ããããç€ºãææšã§ããããã¶ãŒãæ¯ã1ã§ããã°2矀éã«å·®ããªãããšã瀺ãã1以äžã§ããã°èª¿æ»å¯Ÿè±¡ã®ä»çŸ€ãšæ¯èŒããŠãªã¹ã¯ãäœãããšã瀺ãã1以äžã§ããã°ãªã¹ã¯ãé«ãããšã瀺ãã
ä¿¡é ŒåºéïŒconfidence intervalïŒ ä¿¡é Œåºéãšã¯ã調æ»ãããŠããæªç¥ã®æ¯éå£ãã©ã¡ãŒã¿ã®æšå®ç¯å²ããããäŸãã°ãä¿¡é Œåºé95ïŒ ãšã¯ã調æ»å¯Ÿè±¡ã®ãã©ã¡ãŒã¿ããã®ç¯å²ã«å ¥ã確çã95ïŒ ã§ããããšãæå³ããã
Children's Health Defenseã®ã·ãã¢ã»ãªãµãŒãã»ãµã€ãšã³ãã£ã¹ãã§ããã«ãŒã«ã»ãžã£ããããŠã¹ããŒå士ã¯ããDefenderãçŽã«å¯Ÿããããã¡ã€ã¶ãŒã»ãã€ãªNTããã¯ãæ¥çš®ããçåŸ6ã¶æãã4æ³ãŸã§ã®åäŸããçç¶ã®ããCOVID-19ãšèšºæãããå¯èœæ§ã191ïŒ é«ããšããçµ±èšçã«ææãªã·ã°ãã«ã«çžåœããããšè¿°ã¹ãã
Jablonowskiæ°ã«ããã°ããã®æèŠã¯èè ã®äžå¿çãªäž»åŒµã§ãããã¯ã¯ãã³æ¥çš®å ãšæªæ¥çš®å ã®éã« ããªã¹ã¯ã®å·®ã¯ãªãã£ã ããšããããšããããŠCOVID-19ã¯ã¯ãã³æ¥çš®ã¯ ãéçåãæããããã« ãäŸç¶ãšããŠæãŸãããšããããšã«çåãæãããããã®ã§ãããšããã
ããªã¹ã¯ã«å·®ã¯ãªã "ãšãã声æã¯äžäœçºã®åã§ããããã¯ã¯ãã³æ¥çš®ãåããå°å ããããå€ãã®çåæ§ãã€ãŸãããéçã®ææçã«ããã£ãŠããããšã¯ãç¡èŠã§ããªãåŸåã§ããã
ãã®ç ç©¶ã¯ãŸã次ã®ãããªçµæãåºããŠããïŒ
COVID-19ã«ææããããšã®ãªãåäŸãã¡ïŒããã€ãŒããªåå è ããšåŒã°ããïŒã®ãã¡ããã¡ã€ã¶ãŒã»ãã€ãªNTechã¯ã¯ãã³ãæ¥çš®ããåäŸãã¡ã¯ããã€ãŒããªåå è ãã¯ã¯ãã³æªæ¥çš®ã®åå è ã«æ¯ã¹ãŠãCOVID-19ã«ææããçåæ§ã®COVID-19ãçµéšããå¯èœæ§ãé«ãã£ãã
Substackã«æçš¿ãããåæã§ãHulscheræ°ã¯ãCOVID-19æææŽã®ãªãã¯ã¯ãã³æ¥çš®å ã¯ããæææŽã®ãªãã¯ã¯ãã³æªæ¥çš®å ãšæ¯èŒããŠãææããå¯èœæ§ã159ïŒ é«ããçåæ§COVID-19ãçºçããå¯èœæ§ã257ïŒ é«ãã£ã ããšããç ç©¶çµæã瀺ãããšè¿°ã¹ãã
COVID-19æææŽã®ããã¯ã¯ãã³æªæ¥çš®ã®å°å ã¯ãã¯ã¯ãã³æªæ¥çš®ãã€æææŽã«ããå ç«ã®ãªãå°å ãšæ¯èŒããŠãæ°èŠææïŒHR 0.28ã95% CI 0.16-0.49ïŒããã³çåæ§çŸæ£ïŒHR 0.21ã95% CI 0.08-0.54ïŒã®ãªã¹ã¯ãææã«äœãã£ãã
ãã¡ã€ã¶ãŒç€Ÿã®2䟡ããŒã¹ã¿ãŒãå°ãªããšã1ååããå°å ã§ã¯ãCOVID-19ææçïŒHR 0.74ã95ïŒ CI 0.37-1.48ïŒãçç¶ïŒHR 1.04ã95ïŒ CI 0.37-2.96ïŒã®ææãªæžå°ã¯èªããããªãã£ãã
TrialSite Newsã®åµèšè å Œçºè¡äººã§ããDaniel O'Connoræ°ã¯ããã®ç ç©¶ã¯çåãåããŠãããšè¿°ã¹ãããèè ãã¯ãªãæåã®æé²ã§çµæã軜èŠããã®ãïŒãªããã¥ãŒã¹ã®äžé¢ã食ããªãã®ãïŒ
ãã«ã·ã£ãŒã¯ãCDCã®ç§åŠè ããã®ç ç©¶ãå·çããããšã¯éèŠã§ãããšè¿°ã¹ãããããã¯ãå ¬è¡è¡çæ©é¢ã®å€ãã®ç§åŠè ããããšããããéå€§ãªæå³ãæã€ãã®ã§ãã£ãŠããçå®ãå ±åããããšã«å šåãå°œãããŠããããšã瀺ããŠããã
éçã¯ãããã®ã®ãç ç©¶ã¯éèŠãªåé¡ãæèµ·
ãã®ç ç©¶ã®èè ãã¯ããµã³ãã«ãµã€ãºãå°ããããšãæéã®çµéã«äŒŽãæäœã® ãè¡°ã ãã«ããCOVID-19ã®å è¡ææããã¹ãŠæ€åºã§ããªãå¯èœæ§ãããããšãªã©ãããã€ãã®é倧ãªéçãææããŠããã
TrialSite Newsã«æ²èŒãããåæã§ãO'Connoræ°ã¯ãã®ç ç©¶ã®éçãããã«ããã€ãææããã
O'Connoræ°ã¯ãããã®ç ç©¶ã§ã¯ãã¯ã¯ãã³æªæ¥çš®çŸ€ãšã¯ã¯ãã³æ¥çš®çŸ€ãåçšåºŠã®ãŠã€ã«ã¹ãžã®æŽé²ãåãããšä»®å®ããŠããããå®¶æã®è¡åããªã¹ã¯èªç¥ã®éãã«ããããããåœãŠã¯ãŸããªãå¯èœæ§ãããããšæžããŠããã
O'Connoræ°ã¯ããã®ç ç©¶ã§ã¯ãç ç©¶åœæã«æµè¡ããŠããCOVID-19ã®å€ç°åã§ããXBBã®åœ±é¿ã枬å®ããŠããªãå¯èœæ§ãããããã¯ã¯ãã³æ ªãšã¯éºäŒçã«ç°ãªã£ãŠãããæœåšçãªã¯ã¯ãã³å¹æãæžå°ãããŠããããšè¿°ã¹ãã
圌ã¯ãŸãããã¯ã¯ãã³æ¥çš®ãéžæãã芪ããæŽé²ããªã¹ã¯ã«åœ±é¿ããä»ã®è¡åããšãå¯èœæ§ããã ããšãã ãå¥åº·ãªãŠãŒã¶ãŒãã€ã¢ã¹ ãã®ãããªãµã³ãã«å ã«å åšãããã€ã¢ã¹ããããããããªããšè¿°ã¹ãã
ãéå æãã€ãŸãã¯ã¯ãã³æ¥çš®ãåããåäŸã¯ããé »ç¹ã«æ€æ»ãåããææãçºèŠããå¯èœæ§ãé«ãŸã£ãå¯èœæ§ãããããšãªã³ããŒæ°ã¯æžããŠããã
Kulldorffæ°ã¯ãŸãããã®ç ç©¶ã§ã¯ã¯ã¯ãã³æ¥çš®å ãšæªæ¥çš®å ã®å ¥é¢çã®æ¯èŒã«é¢ããçåã«ã¯çããŠããªããšææããã
ãCOVIDã¯ã¯ãã³ã¯ãCOVIDææãçåæ§çŸæ£ãæžå°ããããã©ããã§ã¯ãªããCOVIDã«ããå ¥é¢ãæ»äº¡ãæžå°ããããã©ããã§å€æãããã¹ãã§ãããæšå¥šãããã¹ãã§ã¯ãªãããšKulldorffæ°ã¯è¿°ã¹ãããåœåã®ç¡äœçºå詊éšãšåæ§ã«ããã®ç ç©¶ã¯ãã®åŸè ã®éèŠãªåé¡ã«ã€ããŠã®æ å ±ãæäŸããŠããªãã
ãã«ã·ã£ãŒã¯ããã®ç ç©¶çµæã¯2023幎ã®ã¯ãªãŒãã©ã³ãã»ã¯ãªããã¯ã®ç ç©¶çµæãè£ä»ãããã®ã§ãããšè¿°ã¹ãã
ãåŸã£ãŠããµã³ãã«æ°ã®å€ãä»åŸã®ç ç©¶ã§ãåæ§ã®çµæãåŸããããšæåŸ ãããŸãããšHulscheræ°ã¯è¿°ã¹ãã
ãã®ç ç©¶ã¯ãã¡ã€ã¶ãŒç€Ÿã®COVID-19ã¯ã¯ãã³ã ãã«çŠç¹ãåœãŠããã®ã§ããããHulscheræ°ã¯ããä»ã®mRNA泚å°ãåãäœçšæ©åºã«äŸåããŠããã®ã§ãåæ§ã®çµæãåŸãããã ãã ããšè¿°ã¹ãã
å°éå®¶ã¯ãŸãããã®ç ç©¶çµæã¯ãæè¿mRNA補å€ã®æäžãã¢ã©ããªã¢ã ïŒäžæåæ¢ïŒããããåŒã³ãããŠããããšã«å¯äžãããã®ã§ãããšãè¿°ã¹ãŠããã
ããã®ç ç©¶ã¯ããã¹ãŠã®mRNA泚å°ãåžå Žããæé€ããããšãç·æ¥ã«å¿ èŠã§ããããšã瀺ãèšå€§ãªèšŒæ ã«å ãããã®ã§ãã
ããã®ç ç©¶ã«åºã¥ããŠãã¯ã¯ãã³æ¥çš®ãæ¬åœã«æææåæ§ãå¢å ããããã©ããã倿ãããŸã§ãå°å ãžã®COVID-19ã¯ã¯ãã³æ¥çš®ãäžæ¢ããããšã決å®çã«éèŠã§ããã